Taking a treatment from the laboratory in to clinical trials and then to becoming available for use is a complex and expensive process. We talk with Dr Kiran Reddy, President and CEO of Praxis Precision Medicines, about the plans for the RC-222 treatment program with the eventual goal of having a treatment available for SCN2A gain-of-function epilepsies.

Hosted by Kris Pierce and David Cunnington, parents of Will, who has SCN2A.

Leave a review and subscribe via Apple Podcasts. 

You can also find SCN2A Insights on Spotify, and Google Podcasts or in your podcast app

Links: 

• Praxis Precision Medicines
• Antisense oligonucleotide therapy for gain-of-function SCN2A epilepsies
• Natural History Study – podcast on SCN2A natural history study

See omnystudio.com/listener for privacy information.